Clinical trials: Refractory Brain Neoplasm
Glioblastoma Multiforme, Anaplastic Astrocytoma
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults.
- Trial name
- NCT01269853
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Northwell Health
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Disseminated Encephalomyelitis, Devic's Syndrome
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
OBJECTIVES: I. Evaluate the effectiveness of plasma exchange in the treatment of acute severe attacks of inflammatory demyelinating disease in patients who have failed intravenous steroid therapy.
- Conditions
- Acute Disseminated Encephalomyelitis, Devic's Syndrome, Marburg's Variant of Multiple Sclerosis, Balo's Concentric Sclerosis
- Trial name
- NCT00004645
- Testing
- Plasma exchange
- Volunteers
- 22 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
- Conditions
- Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
- Trial name
- NCT06838676
- Testing
- ACT001
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Nationwide Children's Hospital
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tumors, Brain Tumors
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated.
- Conditions
- Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00187174
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Glioma of Brain, Colorectal Carcinoma
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Malignant Glioma of Brain, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT02617134
- Testing
- anti-MUC1 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Astrocytoma, Anaplastic Astrocytoma
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high…
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT02684058
- Testing
- Dabrafenib, trametinib, Carboplatin
- Where
- 57 sites in United States, Argentina and 18 more
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all…
- Conditions
- Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor
- Trial name
- COZMOS (NCT03206021)
- Testing
- 5 Azacytidine
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- The Hospital for Sick Children
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03016741
- Testing
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Sarcoma, Neuroblastoma
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Background: Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT01130623
- Testing
- Pazopanib (GW786034)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
This phase II trial studies how well bevacizumab and atezolizumab with or without cobimetinib work in treating patients with untreated melanoma that has spread to the brain (brain metastases).
- Conditions
- BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT03175432
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University